Entero Healthcare
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Entero Healthcare Solutions is navigating a transformative phase, transitioning from a pure pharmaceutical distributor to a diversified healthcare platform. Management's focus on integrating high-margin MedTech products and leveraging technology for operational efficiencies is expected to drive revenue growth, with a target of 23% YoY for FY27. This strategic pivot is supported by structural tailwinds in the Indian healthcare sector, including rising insurance coverage and a shift towards organized distribution. However, challenges such as the complexity of M&A integration and regulatory pressures could impact margins and operational execution. Vista's financial outlook reflects stable margins and a fair valuation, with an expected upside of approximately 1.3%. Over the next 12-24 months, key opportunities include expanding the MedTech portfolio and optimizing the supply chain, while watchpoints involve managing integration risks and maintaining disciplined capital allocation amidst competitive pressures
Why We Like This Stock
- Management's focus on integrating high-margin MedTech products is expected to enhance revenue and margins
- The company's technology-driven approach aims to optimize supply chain efficiencies and improve operational performance
- Structural tailwinds in the Indian healthcare sector, such as increased insurance coverage, support long-term growth prospects
Things To Watch Out For
- Integration complexities from recent acquisitions pose risks to achieving projected synergies and operational efficiency
- Regulatory pricing pressures could impact margins and overall profitability
- Increased competition in the MedTech sector may challenge margin stability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,922 | 5,096 | 6,591 | 7,327 | 8,704 |
| Profit Before Tax (Cr.) | 36 | 139 | 187 | 238 | 288 |
| PBT Margin | 0.9% | 2.7% | 2.8% | 3.2% | 3.3% |
| Net Profit (Cr.) | 22 | 112 | 125 | 158 | 144 |
| Earnings Per Share | 4.9 | 22.9 | 21.6 | 27.3 | 33.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 2,100 | 28-Aug-2026 |
| Jeffries | ▲ Buy | 1,800 | 11-Aug-2026 |
Company Overview
Show Company Profile
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.